Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
None (29) ·
Aptiom (1) ·
Banzel (1) ·
Briviact (1) ·
Cerebyx (1) ·
Depakote (1) ·
Diacomit (1) ·
Dilantin (1) ·
Epidiolex (1) ·
Felbatol (1) ·
Fintepla (1) ·
Fycompa (1) ·
Gabitril (1) ·
ketalar (1) ·
Laudanum, Dropizol (1) ·
Lithobid (1) ·
Luminal (1) ·
Nexus, Eroxan (historical, late-1980s through mid-1990s) (1) ·
Nuedexta (1) ·
Onfi (1) ·
Sabril (1) ·
Ultracet, Tramacet (1) ·
Vimpat (1) ·
Xcopri (1) ·
Zarontin (1) ·
Zonegran (1)
classes: (Click arrow to add another value)
mechanism:
None (1) ·
5-HT2A agonist (12) ·
5-HT2A agonist; long duration (1) ·
5-HT2A agonist; MAO inhibitor (1) ·
5-HT2A agonist; milder than other 2C-x (1) ·
5-HT2A partial agonist (1) ·
5HT1a (1) ·
AMPA receptor antagonist (1) ·
Extremely potent 5-HT2A agonist; vasoconstrictor (1) ·
Extremely potent 5-HT2A agonist; very long duration (1) ·
GABA enhancer; sodium channel blocker; histone deacetylase inhibitor (1) ·
GABA reuptake inhibitor (GAT-1 blocker) (1) ·
GABAA positive allosteric modulator (1) ·
GABAA positive allosteric modulator; lactate dehydrogenase inhibitor (1) ·
GABAA potentiator and direct activator (1) ·
Irreversible GABA-T inhibitor (1) ·
Multiple mechanisms; GPR55 antagonist; TRPV1 agonist (1) ·
NMDA antagonist; GABAA potentiator (1) ·
NMDA-receptor antagonism (1) ·
Potent 5-HT2A agonist (5) ·
Potent 5-HT2A agonist; no oral activity (1) ·
Potent 5-HT2A agonist; very long duration (1) ·
Prodrug of phenytoin; sodium channel blocker (1) ·
Serotonin releaser; sigma-1 agonist (1) ·
Slow-inactivation sodium channel enhancer; CRMP-2 ligand (1) ·
Sodium channel blocker (2) ·
Sodium channel blocker; GABAA positive allosteric modulator (1) ·
Sodium channel modulator (1) ·
Sodium/T-type calcium channel blocker; carbonic anhydrase inhibitor (1) ·
Source of DMT-class tryptamines (1) ·
Source of [[DMT]], bufotenine, and 5-MeO-DMT (1) ·
Source of [[DMT|N,N-dimethyltryptamine]] (1) ·
SV2A ligand (higher affinity than levetiracetam) (1) ·
T-type calcium channel blocker (1) ·
TBD (1) ·
Very potent 5-HT2A agonist; long duration (1) ·
'"`UNIQ--vote-00001580-QINU`"' First FDA-approved treatment for PBA. The 10 mg quinidine daily dose is far below antiarrhythmic levels but sufficient to nearly fully inhibit CYP2D6, the basis of the combination's pharmacokinetic rationale'"`UNIQ--ref-00001581-QINU`"'. (1) ·
µ-opioid agonism (1)
uses:
starting dose:
preparations:
fda max:
routes:
onset:
duration:
halflife:
None (51) ·
Dextromethorphan substantially prolonged by quinidine's CYP2D6 inhibition (typical extensive metabolizers see ~10× higher AUC); quinidine ~6-8 hours'"`UNIQ--ref-00001583-QINU`"' (1) ·
Not well characterized (1) ·
Tramadol ~5-7 hours (M1 metabolite ~9 hours); acetaminophen 1-3 hours'"`UNIQ--ref-00001530-QINU`"' (1)
bioavailability:
pregnancy:
None (51) ·
Avoid; neonatal opioid withdrawal documented.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; quinidine has been used in pregnancy as antiarrhythmic.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Not established (1)
legal:
None (51) ·
[[USLegal:DEA Schedule I|Schedule I]] (United States) (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Caution with QT-prolonging medicines (quinidine itself is class IA antiarrhythmic, and the dose here, though sub-antiarrhythmic, still contributes to QT)'"`UNIQ--ref-00001585-QINU`"' (1) ·
[[USLegal:Schedule IV|Schedule IV controlled substance]] in US (tramadol was reclassified from non-controlled to Schedule IV in 2014 after recognition of dependence risk) (1)
Showing below up to 54 results in range #1 to #54.